An interventional study of collagen crosslinking group and Topical anti-fungal therapy in Mycotic Corneal Ulcer, sponsored by Aravind Eye Care System. Status unknown at 1 site in India. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-12-31.
Sponsored by Aravind Eye Care System · Not applicable, Interventional, and Treatment
The study is a randomised control trial to assess the visual and clinical outcomes of collagen cross linking in fungal keratitis. Fungal keratitis is a major cause of corneal blindness in India and the therapeutic options available are minimal to handle the advanced complications and sequalae caused by the disease.The antimicrobial and tissue remodeling role of corneal cross linking was demonstrated by several studies earlier,we anted to specifically assess the role of corneal cross linking in non resolving fungal keratitis in prevention of perforation and enhancement of healing process.
Patients with culture positive deep stromal fungal keratitis not responding to appropriate medical therapy for a period of two weeks were randomized to receive or not receive adjuvant CXL. The medical therapy was continued in both the groups and were followed up for 6 weeks after randomization. Healing of the ulcer was taken as successful outcome, while perforation and increase in ulcer size of more than 2 sq.mm from the baseline was considered as treatment failure.
57 studies on the registry are indexed under Corneal Ulcer; 8 are open to participants now.
This study's planned enrollment of 20 is below the median of 60 across 45 interventional studies indexed under Corneal Ulcer.
Browse Corneal Ulcer studies →Aravind Eye Care System is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
patients not resolving to standard antifungal therapy were assigned to receive adjuvant collagen crosslinking with riboflavin and Ultraviolet-A along with topical medical therapy
Procedure: collagen crosslinking group · Drug: Topical anti-fungal therapy
patients were continued on topical antifungal therapy namely Natamycin eye drops and voriconazole eye drops
Drug: Topical anti-fungal therapy
collagen crosslinking with riboflavin and Ultraviolet A
Also known as: CXL, C3R
topical antifungal medications like natamycin eye drops and voriconazole eye drops
Also known as: natamycin, voriconazole
size of infiltrate or scar, corneal structural integrity
Time frame: 6 months
visual acuity
Time frame: 6 months
This study is status unknown, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.